November 17-18, 2011: Risk Communication Advisory Committee Meeting Announcement
|November 17-18, 2011||8:00 a.m. - 5:00 p.m.|
Food and Drug Administration
10903 New Hampshire Ave.
Building 31 Conference Center
Great Room (rm. 1503)
Silver Spring, MD 20993
On November 17, 2011, the Committee will discuss results of a literature review (as required in the Patient Protection and Affordable Care Act) about communicating quantitative risk and benefit information in prescription drug promotional labeling and print advertising, and will also receive a briefing on activities in FDA’s Office of Special Health Issues. On November 18, 2011, the Committee will discuss implications, for strategic communication, of recent theoretical developments on information use in decision-making.
Visitors to the White Oak Campus must have a valid driver's license or other picture ID, and must enter through Building 1. Please note visitors can park in the South-west garage near Building 31 or the North-west parking lot near Building 22 (click here for a campus map).
Public Participation Information
Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person on or before November 9, 2011. Oral presentations from the public will be scheduled between approximately 1 p.m. and 2 p.m. on November 17, 2011, and 10:30 a.m. and 11:30 a.m. on November 18, 2011. Those individuals interested in making formal oral presentations should notify the contact person and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation on or before November 3, 2011. to hear and see the proceedings.
Time allotted for each presentation may be limited. If the number of registrants requesting to speak is greater than can be reasonably accommodated during the scheduled open public hearing session, FDA may conduct a lottery to determine the speakers for the scheduled open public hearing session. The contact person will notify interested persons regarding their request to speak by November 4, 2011. Interested persons can also log on to https://collaboration.fda.gov/rcac/
- Lee L. Zwanziger, Designated Federal Official
10903 New Hampshire Avenue, Building 32, Room 3278
Silver Spring, MD 20993
- Phone 301-796-9151
- FAX: 301-847-8611
- FDA Advisory Committee Information Line
301-443-0572 in the Washington, DC, area
Please call the Information Line for up-to-date information on this meeting.